Goldman Sachs analyst Chris Shibutani maintained a Hold rating on BioNTech SE (BNTX - Research Report) today and set a price target of $200.00. The company's shares closed yesterday at $169.30.Shibutani covers the Healthcare sector, focusing on stocks such as BioNTech SE, Pfizer, and Arcutis Biotherapeutics. According to TipRanks, Shibutani has an average return of 23.3% and a 48.28% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $215.11 average price target, implying a 27.06% upside from current levels. In a report released on August 1, J.P.
https://www.tipranks.com/news/blurbs/biontech-se-bntx-receives-a-hold-from-goldman-sachs-4?utm_source=advfn.com&utm_medium=referral
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more BioNTech Charts.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more BioNTech Charts.